ESMOImmuno24,LSCM,Oncology

Mashup Score: 0

Pembrolizumab Plus SBRT Fails to Improve Survival in Unresected Stage I/II NSCLC - 10 hour(s) ago

The addition of pembrolizumab to radiation did not improve survival in unresected, stage I or II non–small cell lung cancer.

Source: www.onclive.com

Categories: General Medicine News, Oncologists1

Tweet Tweets with this article
- OncLive
  
  The addition of pembrolizumab to radiation did not improve survival in unresected, stage I or II non–small cell lung cancer. @myESMO #ESMOImmuno24 #LSCM #Oncology https://t.co/62vczmCWtx